ROYCE LABORATORIES RECEIVES FDA APPROVAL FOR LORAZEPAM IN THREE DOSAGE STRENGTHS
ROYCE LABORATORIES RECEIVES FDA APPROVAL FOR
LORAZEPAM IN THREE DOSAGE STRENGTHS
MIAMI, Nov. 1 /PRNewswire/ -- Royce Laboratories, Inc. (NASDAQ: RLAB) today announced that it has received approval from the Food and Drug Administration for Lorazepam in three dosage strengths (0.5 mg, 1.0 mg, and 2.0 mg).
Lorazepam is the generic equivalent of Ativan, a tranquilizer manufactured by Wyeth Laboratories.
This is the fifth ANDA (Abbreviated New Drug Application) approval that Royce has received in the last seven months, and at the present time Royce has an additional six drugs in various dosage strengths pending with the FDA.
Royce Laboratories, Inc. is a manufacturer of prescription and over-the-counter generic pharmaceuticals.
/CONTACT: Patrick J. McEnany, president of Royce Laboratories, Inc., 305-624-1500/
(RLAB) CO: Royce Laboratories, Inc. ST: Florida IN: MTC SU: AW-MR -- FL003 -- 0084 11/01/91 09:03 EST